title: Manipulation of prothrombin concentration improves response to high-dose factor VIIa in a cell-based model of haemophilia.
abstract: Clinical reports suggest that treatment regimens employing both activated prothrombin complex concentrates (aPCCs) and recombinant activated factor VII (rFVIIa) may control the bleeding in patients with haemophilia who fail to respond to either agent alone. We hypothesised that increased concentrations of prothrombin, as may be observed after the infusion of aPCCs, favourably influence parameters of thrombin generation in haemophilia treated with high-dose rFVIIa. We examined the effect of varied prothrombin and rFVIIa concentrations on thrombin generation in a model of haemophilia. At all concentrations of rFVIIa, increased prothrombin concentrations led to increases in the peak and rate of thrombin generation. In assays with the highest concentrations of prothrombin and rFVIIa, peak thrombin actually equalled that measured in the model of normal haemostasis. The significant impact of prothrombin concentration on the effect of rFVIIa in vitro may explain the improved haemostasis reported with concurrent use of aPCCs and rFVIIa. These results imply that persons with plasma prothrombin levels at either end of the 'normal' range could have significantly different responses to similar rFVIIa doses. Furthermore, these results suggest that increasing plasma prothrombin concentration prior to rFVIIa administration may offer advantages over the use of rFVIIa alone in the treatment of haemophilic bleeding.
authors.affiliation: Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA. gallen@childrensmemorial.org
authors.forename: Geoffrey A
authors.initials: GA
authors.lastname: Allen
authors.forename: Maureane
authors.initials: M
authors.lastname: Hoffman
authors.forename: Harold R
authors.initials: HR
authors.lastname: Roberts
authors.forename: Dougald M
authors.initials: DM
authors.lastname: Monroe
mesh_terms: D001792:Blood Platelets / Q000378:metabolism; D002478:Cells, Cultured; D004334:Drug Administration Schedule; D005167:Factor VII / Q000008:administration & dosage* / Q000627:therapeutic use; D015942:Factor VIIa; D006467:Hemophilia A / Q000378:metabolism / Q000628:therapy*; D006487:Hemostasis; D006801:Humans; D008954:Models, Biological; D009000:Monocytes / Q000378:metabolism; D011516:Prothrombin / Q000008:administration & dosage* / Q000627:therapeutic use; D011994:Recombinant Proteins / Q000008:administration & dosage / Q000627:therapeutic use; D013917:Thrombin / Q000032:analysis / Q000096:biosynthesis; D013925:Thromboplastin / Q000378:metabolism
chemical_list: D011994:Recombinant Proteins; D005167:Factor VII; D011516:Prothrombin; D013925:Thromboplastin; C103587:recombinant FVIIa; D015942:Factor VIIa; D013917:Thrombin